[小细胞肺癌的最新进展与未来策略]
[Recent Advances and Future Strategies for Small Cell Lung Cancer].
作者信息
Shao Weipeng, Wang Xiaowei, Liu Deruo
机构信息
Department of Thoracic Surgery, China-Japan Friendship Hospital, Peking University Health Science Center (PUSHC), Beijing 100029, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2017 Jun 20;20(6):421-426. doi: 10.3779/j.issn.1009-3419.2017.06.09.
Abstract
Small cell lung cancer (SCLC) is a malignant tumor with a very high mortality rate. The current standard of care includes surgery, chemotherapy and radiotherapy. The clinical benefit of therapies was disappointing. Recently, many clinical trials about target therapy and immunotherapy are processing. This review will focus on current therapy and future research direction of SCLC.
摘要
小细胞肺癌（SCLC）是一种死亡率极高的恶性肿瘤。目前的治疗标准包括手术、化疗和放疗。这些治疗方法的临床获益令人失望。最近，许多关于靶向治疗和免疫治疗的临床试验正在进行中。本综述将聚焦于小细胞肺癌的当前治疗及未来研究方向。
相似文献
1
[Recent Advances and Future Strategies for Small Cell Lung Cancer].[小细胞肺癌的最新进展与未来策略]
Zhongguo Fei Ai Za Zhi. 2017 Jun 20;20(6):421-426. doi: 10.3779/j.issn.1009-3419.2017.06.09.
2
Current and future therapeutic approaches for the treatment of small cell lung cancer.小细胞肺癌治疗的当前和未来治疗方法。
Expert Rev Anticancer Ther. 2018 May;18(5):473-486. doi: 10.1080/14737140.2018.1453361. Epub 2018 Mar 20.
3
Small Cell Lung Cancer: Advances in Diagnosis and Management.小细胞肺癌：诊断与管理的新进展。
Semin Respir Crit Care Med. 2020 Jun;41(3):435-446. doi: 10.1055/s-0039-1700566. Epub 2020 May 25.
4
Cooperative group research endeavors in small-cell lung cancer: current and future directions.小细胞肺癌的协作组研究努力：当前和未来的方向。
Clin Lung Cancer. 2009 Sep;10(5):322-30. doi: 10.3816/CLC.2009.n.044.
5
Treatment options for small cell lung cancer - do we have more choice?小细胞肺癌的治疗选择——我们有更多选择吗？
Br J Cancer. 2010 Feb 16;102(4):629-38. doi: 10.1038/sj.bjc.6605527. Epub 2010 Jan 26.
6
Treatment advances in small cell lung cancer (SCLC).小细胞肺癌（SCLC）的治疗进展。
Pharmacol Ther. 2017 Dec;180:16-23. doi: 10.1016/j.pharmthera.2017.06.002. Epub 2017 Jun 1.
7
Small cell lung cancer: new clinical recommendations and current status of biomarker assessment.小细胞肺癌：新的临床建议和生物标志物评估的现状。
Eur J Cancer. 2011 Sep;47 Suppl 3:S272-83. doi: 10.1016/S0959-8049(11)70173-3.
8
[Advances in Molecular Subtyping, Characteristics and Therapeutic Strategies of
Small Cell Lung Cancer].[小细胞肺癌分子分型、特征及治疗策略的研究进展]
Zhongguo Fei Ai Za Zhi. 2023 Apr 20;26(4):303-309. doi: 10.3779/j.issn.1009-3419.2023.106.08.
9
A new hope: the immunotherapy in small cell lung cancer.新希望：免疫疗法在小细胞肺癌中的应用。
Neoplasma. 2016;63(3):342-50. doi: 10.4149/302_151001N511.
10
Prospects of targeted and immune therapies in SCLC.小细胞肺癌的靶向和免疫治疗前景。
Expert Rev Anticancer Ther. 2019 Feb;19(2):151-167. doi: 10.1080/14737140.2019.1559057. Epub 2018 Dec 28.
引用本文的文献
1
[Prognostic Analysis of Lobectomy versus Sublobar Resection in Patients Aged ≥60 Years with Stage Ia Small Cell Lung Cancer].≥60岁的Ia期小细胞肺癌患者肺叶切除术与肺段切除术的预后分析
Zhongguo Fei Ai Za Zhi. 2018 Jan 20;21(1):8-15. doi: 10.3779/j.issn.1009-3419.2018.01.02.
本文引用的文献
1
Effects of aspirin on small-cell lung cancer mortality and metastatic presentation.阿司匹林对小细胞肺癌死亡率和转移表现的影响。
Lung Cancer. 2017 Apr;106:67-69. doi: 10.1016/j.lungcan.2017.01.018. Epub 2017 Feb 4.
2
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.上皮-间质转化（EMT）、ATM和SLFN11的动态变化决定了小细胞肺癌对PARP抑制剂和顺铂的反应。
Oncotarget. 2017 Apr 25;8(17):28575-28587. doi: 10.18632/oncotarget.15338.
3
High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.在186例小细胞肺癌病例中，程序性死亡受体配体1（PD-L1）高表达与IV期疾病及较差的总生存期相关。
Oncotarget. 2017 Mar 14;8(11):18021-18030. doi: 10.18632/oncotarget.14935.
4
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.意大利多中心三期随机研究：顺铂联合依托泊苷加或不加贝伐珠单抗作为广泛期小细胞肺癌一线治疗：GOIRC-AIFA FARM6PMFJM 试验。
J Clin Oncol. 2017 Apr 20;35(12):1281-1287. doi: 10.1200/JCO.2016.69.4844. Epub 2017 Jan 30.
5
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.MYC驱动小细胞肺癌向一种对极光激酶抑制敏感的变异神经内分泌亚型发展。
Cancer Cell. 2017 Feb 13;31(2):270-285. doi: 10.1016/j.ccell.2016.12.005. Epub 2017 Jan 12.
6
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
7
Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.巴瑞替尼（AZD1152），一种小分子极光激酶B抑制剂，在体外和体内均可抑制小细胞肺癌细胞系的生长。
Mol Cancer Ther. 2016 Oct;15(10):2314-2322. doi: 10.1158/1535-7163.MCT-16-0298. Epub 2016 Aug 5.
8
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.三期随机临床试验：伊匹单抗联合依托泊苷和铂类药物与安慰剂联合依托泊苷和铂类药物治疗广泛期小细胞肺癌。
J Clin Oncol. 2016 Nov 1;34(31):3740-3748. doi: 10.1200/JCO.2016.67.6601.
9
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.PARP抑制剂活性与SLFN11表达相关，并在小细胞肺癌中与替莫唑胺表现出协同作用。
Clin Cancer Res. 2017 Jan 15;23(2):523-535. doi: 10.1158/1078-0432.CCR-16-1040. Epub 2016 Jul 20.
10
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.纳武利尤单抗单药治疗及纳武利尤单抗联合伊匹单抗治疗复发性小细胞肺癌（CheckMate 032）：一项多中心、开放标签、Ⅰ/Ⅱ期试验。
Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4.
Zotero 插件